futuximab/modotuximab mixture

{
  "id": "MLC-T-ONC-013795",
  "term": "futuximab/modotuximab mixture",
  "field": "Oncology and biomedicine",
  "definition": "A mixture of two recombinant IgG1 antibodies directed against different epitopes in the epidermal growth factor receptor (EGFR) extracellular domain III, with potential antineoplastic activity. Anti-EGFR monoclonal antibody mixture Sym004 binds to the extracellular domain of EGFR, thereby preventing ligand binding. This may prevent activation and subsequent dimerization of the receptor; the decrease in receptor activation may result in an inhibition of downstream ERK and JNK signaling pathways and thus inhibition of EGFR-dependent tumor cell proliferation and metastasis. In addition, binding of Sym004 to EGFRs causes EGFR internalization and degradation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types.",
  "synonyms": [
    "anti-EGFR monoclonal antibody mixture Sym004",
    "futuximab/modotuximab",
    "futuximab/zatuximab"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/futuximab-modotuximab-mixture/"
}